Human pregnane X receptor genotype of the donor but not of the recipient is a risk factor for delayed graft function after renal transplantation

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 5, 2012, Pages 905-916

  Hauser, I A ^a   Kruck, S ^b   Gauer, S ^a   Nies, A T ^c,d   Winter, S ^c,d   Bedke, J ^b   Geiger, H ^a   Hoefeld, H ^a   Kleemann, J ^a   Asbe Vollkopf, A ^a   Engel, J ^a   Burk, O ^c,d   Schwab, M ^b,c   Schaeffeler, E ^c,d  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PREGNANE X RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DONOR; FEMALE; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

ADOLESCENT; ADULT; AGED; DELAYED GRAFT FUNCTION; FEMALE; GENOTYPE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; P-GLYCOPROTEIN; RECEPTORS, STEROID; RISK FACTORS; TISSUE DONORS;

EID: 84860012327     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.346     Document Type: Article

References (50)

1. Perico, N., Cattaneo, D., Sayegh, M.H., Remuzzi, G. Delayed graft function in kidney transplantation. Lancet 364, 1814-1827 (2004).
2. Y arlagadda, S.G. et al. Marked variation in the definition and diagnosis of delayed graft function: a systematic review. Nephrol. Dial. Transplant. 23, 2995-3003 (2008).
3. Ghods, A.J., Savaj, S., Abbasi, M., Heidari, H. & Rokhsatyazdi, H. The incidence and risk factors of delayed graft function in 689 consecutive living unrelated donor renal transplantation. Transplant. Proc. 39, 846-847 (2007).
4. Jevnikar, A.M. & Mannon, R.B. Late kidney allograft loss: what we know about it, and what we can do about it. Clin. J. Am. Soc. Nephrol. 3 (suppl. 2), S56-S67 (2008).
5. Loverre, A. et al. Ischemia-reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: differential modulation by rapamycin. J. Am. Soc. Nephrol. 15, 2675-2686 (2004).
6. Gonwa, T. et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 75, 2048-2053 (2003).
7. Kamar, N. et al. Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: a randomized, multicenter study. Am. J. Transplant. 6, 1042-1048 (2006).
8. Sandrini, S. Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review. Clin. Transplant. 19, 705-710 (2005).
9. Merkus, J.W., Hoitsma, A.J. & Koene, R.A. Detrimental effect of acute renal failure on the survival of renal allografts: influence of total ischaemia time and anastomosis time. Nephrol. Dial. Transplant. 6, 881-886 (1991).
10. Schwab, M., Eichelbaum, M. & Fromm, M.F. Genetic polymorphisms of the human MDR1 drug transporter. Annu. Rev. Pharmacol. Toxicol. 43, 285-307 (2003).
11. Staatz, C.E., Goodman, L.K. & Tett, S.E. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin. Pharmacokinet. 49, 141-175 (2010).
12. Cattaneo, D. et al.; Mycophenolate Steroids Sparing (MYSS) Genetics Study Group. ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J. Am. Soc. Nephrol. 20, 1404-1415 (2009).
13. Naesens, M., Lerut, E., de Jonge, H., Van Damme, B., Vanrenterghem, Y. &Kuypers, D.R. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J. Am. Soc. Nephrol. 20, 2468-2480 (2009).
14. Hauser, I.A. et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J. Am. Soc. Nephrol. 16, 1501-1511 (2005).
15. Woillard, J.B. et al. Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up. Clin. Pharmacol. Ther. 88, 95-100 (2010).
16. Cascorbi, I. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb. Exp. Pharmacol. (201), 261-283 (2011).
17. Kimchi-Sarfaty, C. et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315, 525-528 (2007).
18. Nies, A.T., Schwab, M. & Keppler, D. Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin. Drug Metab. Toxicol. 4, 545-568 (2008).
19. Grisk, O. et al. Multidrug resistance-related protein 2 genotype of the donor affects kidney graft function. Pharmacogenet. Genomics 19, 276-288 (2009).
20. Ma, X., Idle, J.R. & Gonzalez, F.J. The pregnane X receptor: from bench to bedside. Expert Opin. Drug Metab. Toxicol. 4, 895-908 (2008).
21. Lamba, J., Lamba, V., Strom, S., Venkataramanan, R. & Schuetz, E. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab. Dispos. 36, 169-181 (2008).
22. Hustert, E. et al. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos. 29, 1454-1459 (2001).
23. Dring, M.M. et al. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 130, 341-348; quiz 592 (2006).
24. Sookoian, S., Castaño, G.O., Burgueño, A.L., Gianotti, T.F., Rosselli, M.S. & Pirola, C.J. The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenet. Genomics 20, 1-8 (2010).
25. Staatz, C.E., Goodman, L.K. & Tett, S.E. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin. Pharmacokinet. 49, 207-221 (2010).
26. Kast, H.R. et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 277, 2908-2915 (2002).
27. Wallace, K. et al. The PXR is a drug target for chronic inflammatory liver disease. J. Steroid Biochem. Mol. Biol. 120, 137-148 (2010).
28. Haehner, B.D. et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol. Pharmacol. 50, 52-59 (1996).
29. Koziolek, M.J., Riess, R., Geiger, H., Thévenod, F. & Hauser, I.A. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Kidney Int. 60, 156-166 (2001).
30. Siegsmund, M. et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J. Am. Soc. Nephrol. 13, 1847-1854 (2002).
31. Zhang, B., Xie, W. & Krasowski, M.D. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 9, 1695-1709 (2008).
32. Press, R.R. et al. Explaining variability in ciclosporin exposure in adult kidney transplant recipients. Eur. J. Clin. Pharmacol. 66, 579-590 (2010).
33. Fanta, S. et al. Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism. J. Clin. Pharmacol. 50, 581-597 (2010).
34. Wright, M.C. The impact of pregnane X receptor activation on liver fibrosis. Biochem. Soc. Trans. 34, 1119-1123 (2006).
35. Csencsits, K. et al. Transforming growth factor beta-induced connective tissue growth factor and chronic allograft rejection. Am. J. Transplant. 6, 959-966 (2006).
36. Duffield, J.S. et al. Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. J. Clin. Invest. 115, 1743-1755 (2005).
37. Durrbach, A. et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am. J. Transplant. 10, 547-557 (2010).
38. Vincenti, F. et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am. J. Transplant. 10, 535-546 (2010).
39. Bouamar, R. et al. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation. Ther. Drug Monit. 33, 178-184 (2011).
40. Hesselink, D.A. et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet. Genomics 18, 339-348 (2008).
41. Remuzzi, G. et al.; Dual Kidney Transplant Group. Long-term outcome of renal transplantation from older donors. N. Engl. J. Med. 354, 343-352 (2006).
42. Pieringer, H. & Biesenbach, G. Risk factors for delayed kidney function and impact of delayed function on patient and graft survival in adult graft recipients. Clin. Transplant. 19, 391-398 (2005).
43. Parekh, J., Bostrom, A. & Feng, S. Diabetes mellitus: a risk factor for delayed graft function after deceased donor kidney transplantation. Am. J. Transplant. 10, 298-303 (2010).
44. van Gelder, T. et al. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation. Ther. Drug Monit. 33, 155-164 (2011).
45. Geddes, C.C., Woo, Y.M. & Jardine, A.G. The impact of delayed graft function on the long-term outcome of renal transplantation. J. Nephrol. 15, 17-21 (2002).
46. Herrlinger, K.R. et al. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clin. Pharmacol. Ther. 89, 422-428 (2011).
47. Geisler, T. et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 9, 1251-1259 (2008).
48. Kruck, S. et al. Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression. Oncol. Rep. 23, 159-163 (2010).
49. Barrett, J.C., Fry, B., Maller, J. & Daly, M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005).
50. Holm, S. A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics 6, 65-70 (1979).